Apimeds to issue 350,000 unregistered shares to FreeT for Apitox rights
APUS•Apimeds Pharmaceuticals US will issue 350,000 common shares to FreeT by Dec. 1, 2026, as an initial payment for Apitox-related rights. An independent valuer will assess the rights, and any value above the initial payment requires additional consideration.
1. Share issuance and valuation
Apimeds Pharmaceuticals US will issue 350,000 common shares to FreeT by Dec. 1, 2026, as initial payment for Apitox-related rights. Under a Nov. 12, 2026, amendment, the parties must jointly appoint an independent valuer within 60 days. If the valuation exceeds the initial payment, Apimeds must provide additional consideration within 30 days of the valuation’s completion, in cash, common stock or both; the company may choose the payment form. The issuance is exempt from Securities Act registration under Section 4(a)(2).




